< Back to search results

Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

The safety and efficacy of bimekizumab in psoriatic arthritis (PsA) have not been established and it is not approved for use in PsA by any regulatory authority worldwide.  The material below is provided in response to your specific search for information on UCBCOMPASS®.  It is not intended to draw any conclusion regarding the efficacy and safety of bimekizumab for any indication, dosage, or other claim.

View PDF
Download